Showing results (581-590 of 3,788) with videos related to

Sort By:
Pageof 379
Oncoimmunology|December 19, 2022
Cellular senescence enhances adaptive anticancer immunosurveillanceInes Marin, Manuel Serrano, Federico Pietrocola
Oncoimmunology|December 22, 2022
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancerGuanpeng Wang, Yeni Romero, Indhujah Thevarajan, et al.
Oncoimmunology|December 5, 2022
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade responseSofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, et al.
Oncoimmunology|May 9, 2022
Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cellsKarthikeyan Subbarayan, Chiara Massa, Sandra Leisz, et al.
Oncoimmunology|July 8, 2022
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtypeSandra van Wilpe, Donjetë Simnica, Peter Slootbeek, et al.
Oncoimmunology|June 27, 2022
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumorsAnna D Staniszewska, Joshua Armenia, Matthew King, et al.
Oncoimmunology|June 17, 2022
Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progressionZhou Liu, Zhijie Gao, Bei Li, et al.
Oncoimmunology|September 17, 2020
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidatesYago Pico de Coaña, Maria Wolodarski, Irene van der Haar Àvila, et al.
Oncoimmunology|September 17, 2020
Human innate immune cell crosstalk induces melanoma cell senescenceFelix Funck, Jens Pahl, Lenka Kyjacova, et al.
Oncoimmunology|September 16, 2020
Trial watch: TLR3 agonists in cancer therapyJulie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Pageof 379